First, we used eight known enhancer hijacking target genes including MYC (9), BCL2 (8), CCNE1 (37), TERT (7), IGF2 (13,37) (in two tumor types), IGF2BP3 (38) and IRS4 (13) to test the sensitivities. This evidence concerns the gene IGF2BP3 and neoplasm.